Research programme: antibody-drug conjugates - Heidelberg Pharma Research

Drug Profile

Research programme: antibody-drug conjugates - Heidelberg Pharma Research

Alternative Names: ADC - Heidelberg Pharma Research; Antibody-amanitin conjugates

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Heidelberg Pharma
  • Developer Heidelberg Pharma Research; University of Texas M. D. Anderson Cancer Center
  • Class Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Colorectal cancer
  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)
  • 09 Oct 2017 Heidelberg Pharma is now called Heidelberg Pharma Research
  • 18 Oct 2016 Research programme: antibody-drug conjugates - Heidelberg is available for licensing as of 13 Oct 2016. http://www.heidelberg-pharma.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top